Cyclodextrin News

February 6, 2020 CD as API / CD derivatives / Pharma applications / Uncategorized

Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease

Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)

October 25, 2019 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced

September 4, 2019 Drug delivery / Pharma applications

HPBCD is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease

Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin

July 9, 2019 CD as API / Events / Pharma applications

National Niemann Pick Disease Family Conference

The annual National Niemann Pick Disease Family Conference will be held on August 15-18, 2019, in Bloomington, US. The conference

May 30, 2019 CD as API / CD derivatives

Lactosyl-β-cyclodextrin against Hepatomegaly in Niemann-Pick Type C Disease

The first paper in the special issue of Nanomaterials “Nanoconstructs Based on Cyclodextrins” has been published. Mono-lactosyl β-CD (mono-Lac-β-CD) diminished

March 4, 2019 CD as API / Pharma applications / Supramolecular systems

Novel polyrotaxane for Niemann Pick disease type C treatment

The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD